Therapeutic development of adrenomedullin for moderate pneumonia caused by COVID-19

Prevention of aggravation of moderate pneumonia caused by COVID - 19 using adrenomedullin - Investigator initiated phase 2a trial - AM-P2-COVID2

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071210038

Enrollment

Registered

2021-06-24

Start date

2021-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Intravenous infusion of investigative drug (adrenomedullin or placebo) will be started immediately after the allocation of the patient. The administration of the drug are maintained 72 hour and then i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospitalized patients with moderate COVID-19 pneumonia and within 10 days after onset

Exclusion criteria

Exclusion criteria: patients with severe COVID-19 pneumonia patients with liver dysfunction (AST and/or ALT > 5 times of reference values) patients with renal dysfunction (serum creatinine > 2.0 mg/dl) patients with severe ECG abnormalities and/or cardiac diseases patients with malignancy or history of malignancy patients who are expected to transfer to other hospital within 72 hours pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Period of oxygen administration (days)	—

Secondary

Measure	Time frame
the distribution of clinical status assessed on the 6-point ordinal scale on study day 10, 20 and 30 The changes of cytokines Adverse events	—

Contacts

Public ContactToshihiro Kita

University of Miyazaki

toshihiro_kita@med.miyazaki-u.ac.jp+81-985-85-9614

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026